Medpace Holdings, Inc.
MEDP Healthcare Diagnostics & Research
Medpace Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 20.0% from fiscal 2024. In the quarter to June 2026, revenue grew 17.2%, EPS grew 36.4% and free cash flow fell 3.03%, each against the same quarter a year earlier. Revenue growth for ten consecutive years, operating cash flow growth for ten.
Follow MEDP
Medpace Holdings, Inc. (MEDP) EV/Sales
As of 16 October 2026, Medpace Holdings, Inc. (MEDP) trades at a EV/Sales of 6.1×. Over the past ten years it has ranged from 0.0× (September 2016) to 7.3× (November 2025); the current reading is higher than 89% of that period. That is above the Diagnostics & Research industry median of 5.5× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.3× | 35.54% |
| FY2024 | 4.6× | (6.02%) |
| FY2023 | 4.9× | 4.99% |
| FY2022 | 4.7× | (28.00%) |
| FY2021 | 6.5× | 26.42% |
| FY2020 | 5.1× | 49.81% |
| FY2019 | 3.4× | 22.04% |
| FY2018 | 2.8× | (26.75%) |
| FY2017 | 3.8× | 12.53% |
| FY2016 | 3.4× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 5.2× | 6.62% |
| Mar 2026 | 4.9× | (21.64%) |
| Dec 2025 | 6.3× | 3.14% |
| Sep 2025 | 6.1× | 49.59% |
| 39 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ICLR ICON PLC compare | 1.9× |
| LH Labcorp Holdings Inc. compare | 2.2× |
| DGX Quest Diagnostics Incorporated compare | 2.7× |
| CRL Charles River Laboratories International, Inc. compare | 4.2× |
| QGEN QIAGEN N.V. compare | 4.9× |
| MEDP Medpace Holdings, Inc. | 6.1× |
| RVTY Revvity Inc. compare | 6.6× |
| GH Guardant Health, Inc. compare | 18.2× |
| TWST Twist Bioscience Corporation compare | 18.8× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)